Canaccord analyst Whitney Ijem assumed coverage of Ultragenyx (RARE) with a Buy rating and $90 price target, arguing that the company has been built into "an impressive, and truly patient-focused, rare disease company." She likes the combination of a growing top line and multi-modal earlier stage pipeline along with the company’s commitment to R&D spending discipline, likening Ultragenyx to "an earlier stage (baby)" BioMarin (BMRN).
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RARE:
- Buy These 2 Stocks Before They Jump Over 80%, Say Analysts
- Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
- Ultragenyx sees 2023 product revenue $425M-$450M
- Ultragenyx sees 2022 product revenue $352M-$356M
- Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
